Transforming growth factor-beta function blocking already effective as therapeutic strategy.
Cordeiro
M F
MF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000150:complications / Q000188:drug therapy*; D002921:Cicatrix / Q000517:prevention & control; D017326:Clinical Trials, Phase III as Topic; D003971:Diastole; D005355:Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D005901:Glaucoma / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D051381:Rats; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors*; D053781:Transforming Growth Factor beta2; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D016376:Oligonucleotides, Antisense; C509041:TGFB2 protein, human; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2